Weight loss injection in development by Richter and Adalvo

They said the collaboration is built around a shared vision: to shape the future of obesity treatment by providing broad access to high-quality treatment solutions in one of the world’s fastest-growing therapeutic areas. The agreement covers global rights, under which the two companies will share development costs and net profits in each other’s markets.

As part of the agreement, Richter is entitled to use a supply chain selected under the agreement to manufacture the product. However, Richter also reserves the right to manufacture the product in its own facilities for direct distribution under certain conditions.

According to the information, Adalvo was the first to enter the market with this solution and remains committed to developing the market through strategic partnerships. With this collaboration, Gedeon Richter and Adalvo will be well-positioned to meet the growing demand for effective weight management solutions.

Founded in 1901, Richter, headquartered in Hungary, with a market capitalization of EUR 4.7 billion and sales of EUR 2.2 billion in 2024, operates the largest R&D center in Central Europe. It conducts breakthrough research in the fields of neuropsychiatry and gynecology, while biotechnology and generics strengthen the affordable treatment portfolio.

Based in Malta, Adalvo is a global pharmaceutical company and one of Europe’s leading B2B pharmaceutical companies, with operations in more than 130 countries and over 140 trading partners worldwide, the statement said.